Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres

International Journal of Clinical Practice

Volumn 63, Issue 6, 2009, Pages 962-963

  Akhras, K S ^a   Singh, J ^b   Gopal, S ^b   Schadrack, J ^a   Palumbo, J M ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; NEUROLEPTIC AGENT; OLANZAPINE; OLANZAPINE PAMOATE; RISPERIDONE; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION;

CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; INJECTION; LETTER; OUTCOMES RESEARCH; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PUBLICATION; SCHIZOPHRENIA; TREATMENT OUTCOME; DELAYED RELEASE FORMULATION; LITERATURE; METHODOLOGY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; HUMANS; MICROSPHERES; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; RISPERIDONE; SCHIZOPHRENIA;

EID: 65649109710     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02080.x     Document Type: Letter

References (5)

1. Olivares JM, Rodriguez-Martinez A, Diels J et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (eSTAR). European Psychiatry 2009 [Epub ahead of print].
2. Alexander A, Olivares JM, Tuma I et al. Risperidone Long Acting Injection Treatment in Schizophrenia: 12-month Results from the Electronic Schizophrenia Treatment Adherence Registry (ESTAR) (Abstract) 63rd Annual Meeting of Society of Biological Psychiatry, Washington, DC, 1-3 May 2008.
3. Emsely R, Oosthuizen P, Koen L et al. Oral versus injectable antipsychotic treatment in early psychosis: post-hoc comparison of two studies. Clin Ther 2008 30 : 2378 86.
4. Olivares JM, Rodriguez-Martinez A, Buron J et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia. Appl Health Econ Health Policy 2008 6 : 1 13.
5. Medori R, Wapenaar R, de Arce R et al. Relapse prevention and effectiveness in Schizophrenia with risperidone long-acting injectable (RLAI) versus quetiapine (Abstract). Annual Meeting of the Society of Biological Psychiatry, May 1-3, 2008.